PolyPEPI-1012

PolyPEPI-1012 is a **preclinical synthetic peptide cancer vaccine** being developed by Treos Bio as part of its PolyPEPI precision immunotherapy platform. Publicly available pipeline-style sources identify it as a Treos Bio asset in development for **ovarian cancer**, but detailed public disclosures on its exact peptide composition, antigen set, adjuvant, dosing regimen, and clinical development plan appear limited. Based on the broader PolyPEPI platform, the program is intended to induce **multi-antigen, HLA-informed tumor-specific T-cell responses** using selected synthetic peptides designed to stimulate cellular immunity against tumor-associated antigens, but the exact validated targets for PolyPEPI-1012 specifically have not been publicly described in the sources reviewed.